130 related articles for article (PubMed ID: 16709039)
1. Novel therapeutic targets in the brain tumor microenvironment.
Phillips JJ
Oncotarget; 2012 May; 3(5):568-575. PubMed ID: 22643827
[TBL] [Abstract][Full Text] [Related]
2. A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma.
Lenin S; Ponthier E; Scheer KG; Yeo ECF; Tea MN; Ebert LM; Oksdath Mansilla M; Poonnoose S; Baumgartner U; Day BW; Ormsby RJ; Pitson SM; Gomez GA
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919246
[TBL] [Abstract][Full Text] [Related]
3. Exploiting Iron Metabolism as a Therapeutic Vulnerability in Glioblastoma.
Nabavizadeh A; Bagley SJ
Clin Cancer Res; 2024 Jan; 30(2):255-256. PubMed ID: 37982809
[TBL] [Abstract][Full Text] [Related]
4. PinX1-siRNA/mPEG-PEI-SPION combined with doxorubicin enhances the inhibition of glioma growth.
Long L; Wang W; Cai XD; Cheng D; Shuai X; Peng Y
Exp Ther Med; 2014 May; 7(5):1170-1176. PubMed ID: 24940406
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
Wardak Z; Choe KS
Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
[TBL] [Abstract][Full Text] [Related]
6. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFkappaB transcription factors.
Dhandapani KM; Mahesh VB; Brann DW
J Neurochem; 2007 Jul; 102(2):522-38. PubMed ID: 17596214
[TBL] [Abstract][Full Text] [Related]
7. Hypericin uptake: a prognostic marker for survival in high-grade glioma.
Ritz R; Müller M; Dietz K; Duffner F; Bornemann A; Roser F; Tatagiba M
J Clin Neurosci; 2008 Jul; 15(7):778-83. PubMed ID: 18394904
[TBL] [Abstract][Full Text] [Related]
8. Cellular signaling molecules as therapeutic targets in glioblastoma multiforme.
Jagannathan J; Prevedello DM; Dumont AS; Laws ER
Neurosurg Focus; 2006 Apr; 20(4):E8. PubMed ID: 16709039
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
Reardon DA; Wen PY
Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
[TBL] [Abstract][Full Text] [Related]
10. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates.
Simpson L; Galanis E
Expert Rev Anticancer Ther; 2006 Nov; 6(11):1593-607. PubMed ID: 17134364
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
